X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs PANACEA BIOTECH - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES PANACEA BIOTECH DIVIS LABORATORIES/
PANACEA BIOTECH
 
P/E (TTM) x 31.1 142.3 21.8% View Chart
P/BV x 5.4 3.2 170.3% View Chart
Dividend Yield % 0.9 0.0 -  

Financials

 DIVIS LABORATORIES   PANACEA BIOTECH
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
PANACEA BIOTECH
Mar-14
DIVIS LABORATORIES/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs1,222149 821.8%   
Low Rs78482 952.6%   
Sales per share (Unadj.) Rs153.184.1 182.0%  
Earnings per share (Unadj.) Rs39.9-18.3 -218.2%  
Cash flow per share (Unadj.) Rs44.6-6.7 -665.7%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs201.883.7 241.1%  
Shares outstanding (eoy) m265.4761.25 433.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.61.4 477.3%   
Avg P/E ratio x25.1-6.3 -398.0%  
P/CF ratio (eoy) x22.5-17.2 -130.5%  
Price / Book Value ratio x5.01.4 360.2%  
Dividend payout %25.00-   
Avg Mkt Cap Rs m266,2667,074 3,763.8%   
No. of employees `0009.72.8 354.0%   
Total wages/salary Rs m4,6871,449 323.4%   
Avg. sales/employee Rs Th4,175.01,874.1 222.8%   
Avg. wages/employee Rs Th481.5527.0 91.4%   
Avg. net profit/employee Rs Th1,089.3-407.7 -267.1%   
INCOME DATA
Net Sales Rs m40,6435,154 788.6%  
Other income Rs m749100 750.4%   
Total revenues Rs m41,3925,254 787.9%   
Gross profit Rs m14,460-766 -1,887.0%  
Depreciation Rs m1,233711 173.5%   
Interest Rs m231,503 1.5%   
Profit before tax Rs m13,953-2,881 -484.4%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m3,34917 19,935.7%   
Profit after tax Rs m10,604-1,121 -945.7%  
Gross profit margin %35.6-14.9 -239.3%  
Effective tax rate %24.0-0.6 -4,115.5%   
Net profit margin %26.1-21.8 -119.9%  
BALANCE SHEET DATA
Current assets Rs m40,1053,810 1,052.6%   
Current liabilities Rs m6,5958,365 78.8%   
Net working cap to sales %82.5-88.4 -93.3%  
Current ratio x6.10.5 1,335.2%  
Inventory Days Days119156 76.1%  
Debtors Days Days8167 120.0%  
Net fixed assets Rs m19,99514,480 138.1%   
Share capital Rs m53161 866.1%   
"Free" reserves Rs m53,043903 5,873.4%   
Net worth Rs m53,5745,127 1,044.9%   
Long term debt Rs m05,832 0.0%   
Total assets Rs m61,58519,433 316.9%  
Interest coverage x618.4-0.9 -67,474.8%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.70.3 248.9%   
Return on assets %17.32.0 878.5%  
Return on equity %19.8-21.9 -90.5%  
Return on capital %26.13.6 717.4%  
Exports to sales %024.5 0.0%   
Imports to sales %25.210.2 247.9%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs m10,259525 1,954.9%   
Fx inflow Rs m35,3841,539 2,298.8%   
Fx outflow Rs m10,399942 1,103.9%   
Net fx Rs m24,985597 4,183.7%   
CASH FLOW
From Operations Rs m11,493599 1,918.1%  
From Investments Rs m-11,372-438 2,596.8%  
From Financial Activity Rs m-93-303 30.8%  
Net Cashflow Rs m28-141 -20.1%  

Share Holding

Indian Promoters % 52.0 74.5 69.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 0.6 1,966.7%  
FIIs % 19.0 1.3 1,461.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 23.6 72.9%  
Shareholders   31,796 10,259 309.9%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 18, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS